Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 1
2013 1
2014 4
2015 10
2016 4
2017 3
2018 2
2019 1
2020 4
2021 3
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies.
Engdahl TB, Binshtein E, Brocato RL, Kuzmina NA, Principe LM, Kwilas SA, Kim RK, Chapman NS, Porter MS, Guardado-Calvo P, Rey FA, Handal LS, Diaz SM, Zagol-Ikapitte IA, Tran MH, McDonald WH, Meiler J, Reidy JX, Trivette A, Bukreyev A, Hooper JW, Crowe JE. Engdahl TB, et al. Elife. 2023 Mar 27;12:e81743. doi: 10.7554/eLife.81743. Elife. 2023. PMID: 36971354 Free PMC article.
Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
Huttner A, Agnandji ST, Engler O, Hooper JW, Kwilas S, Ricks K, Clements TL, Jonsdottir HR, Nakka SS, Rothenberger S, Kremsner P, Züst R, Medaglini D, Ottenhoff T, Harandi AM, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia. Huttner A, et al. Clin Microbiol Infect. 2023 Dec;29(12):1587-1594. doi: 10.1016/j.cmi.2023.08.026. Epub 2023 Sep 3. Clin Microbiol Infect. 2023. PMID: 37661067
Interaction between respiratory syncytial virus and glycosaminoglycans, including heparan sulfate.
Hallak LK, Kwilas SA, Peeples ME. Hallak LK, et al. Methods Mol Biol. 2007;379:15-34. doi: 10.1007/978-1-59745-393-6_2. Methods Mol Biol. 2007. PMID: 17502668 Review.
Here we describe the rationale and methods for analyzing GAG usage by one such virus, respiratory syncytial virus (RSV). The protocols presented allow the determination of which GAG(s) is employed by the virus, which GAG modification(s) is important, and whether the …
Here we describe the rationale and methods for analyzing GAG usage by one such virus, respiratory syncytial virus (RSV). The protocols prese …
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.
Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVΔG-ZEBOV-GP Study Group. Regules JA, et al. N Engl J Med. 2017 Jan 26;376(4):330-341. doi: 10.1056/NEJMoa1414216. Epub 2015 Apr 1. N Engl J Med. 2017. PMID: 25830322 Free PMC article. Clinical Trial.
Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.
Cong Y, Mucker EM, Perry DL, Dixit S, Kollins E, Byrum R, Huzella L, Kim R, Josleyn M, Kwilas S, Stefan C, Shoemaker CJ, Koehler J, Coyne S, Delp K, Liang J, Drawbaugh D, Hischak A, Hart R, Postnikova E, Vaughan N, Asher J, St Claire M, Hanson J, Schmaljohn C, Eakin AE, Hooper JW, Holbrook MR. Cong Y, et al. Antiviral Res. 2023 May;213:105589. doi: 10.1016/j.antiviral.2023.105589. Epub 2023 Mar 30. Antiviral Res. 2023. PMID: 37003305 Free PMC article.
The COVID-19 pandemic spurred the rapid development of a range of therapeutic antibody treatments. As part of the US government's COVID-19 therapeutic response, a research team was assembled to support assay and animal model development to assess activity for therapeutics …
The COVID-19 pandemic spurred the rapid development of a range of therapeutic antibody treatments. As part of the US government's COV …
Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters.
Brocato RL, Kwilas SA, Kim RK, Zeng X, Principe LM, Smith JM, Hooper JW. Brocato RL, et al. NPJ Vaccines. 2021 Jan 25;6(1):16. doi: 10.1038/s41541-020-00279-z. NPJ Vaccines. 2021. PMID: 33495468 Free PMC article.
Here, a SARS-CoV-2 DNA targeting the spike protein and delivered by jet injection, nCoV-S(JET), elicited neutralizing antibodies in hamsters and was protective in both wild-type and transiently immunosuppressed hamster models. This study highlights the DNA vaccine, nCoV- …
Here, a SARS-CoV-2 DNA targeting the spike protein and delivered by jet injection, nCoV-S(JET), elicited neutralizing antibodies in h …
Humoral immunogenicity of a Coronavirus Disease 2019 (COVID-19) DNA vaccine in rhesus macaques (Macaca mulatta) delivered using needle-free jet injection.
Jay A, Kwilas SA, Josleyn M, Ricks K, Hooper JW. Jay A, et al. PLoS One. 2023 May 31;18(5):e0275082. doi: 10.1371/journal.pone.0275082. eCollection 2023. PLoS One. 2023. PMID: 37256884 Free PMC article.
A SARS-CoV-2 DNA vaccine targeting the spike protein and delivered by jet injection, nCOV-S(JET), previously shown to protect wild-type and immunosuppressed Syrian hamsters (Mesocricetus auratus), was evaluated via two needle-free delivery methods in rhesus macaques (Macac …
A SARS-CoV-2 DNA vaccine targeting the spike protein and delivered by jet injection, nCOV-S(JET), previously shown to protect wild-ty …
40 results